1887

12 : Human Immunodeficiency Virus-Related Opportunistic Infections in the Era of Highly Active Antiretroviral Therapy

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Human Immunodeficiency Virus-Related Opportunistic Infections in the Era of Highly Active Antiretroviral Therapy, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816971/9781555811976_Chap12-1.gif /docserver/preview/fulltext/10.1128/9781555816971/9781555811976_Chap12-2.gif

Abstract:

In the late 1970s, the first clues that an epidemic due to human immunodeficiency virus type 1 (HIV-1) was beginning to unfold were the opportunistic infections that clinicians recognized in previously healthy individuals who, by the laboratory parameters available and in use at the time, appeared to have no underlying disease. Opportunistic infections continue to occur in HIV-infected individuals in the United States in 2000. Epidemiologic data concerning the frequency of opportunistic infections in the era of highly active antiretroviral therapy, as well as specific studies of clinical outcome for patients enrolled in clinical trials, clearly demonstrate that highly active antiretroviral therapy (HAART) reduces susceptibility to opportunistic infection. Viral load is an independent predictor of the likelihood of developing opportunistic infections, but the risk of developing such complications is still effectively predicted by the current CD4 T-lymphocyte count. The revised United States Public Health Service-Infectious Disease Society of America guidelines on prophylaxis of opportunistic infections, which were published in August 1999, continue to stress the importance of initiating primary prophylaxis for pneumocystosis, complex disease, toxoplasmosis, and tuberculosis for patients who meet the well-established criteria.

Citation: Masur H. 2000. Human Immunodeficiency Virus-Related Opportunistic Infections in the Era of Highly Active Antiretroviral Therapy, p 165-186. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 4. ASM Press, Washington, DC. doi: 10.1128/9781555816971.ch12
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1.
Figure 1.

Relationship of CD4 T-lymphocyte count to occurrence of opportunistic infection. The distribution of CD4 T-lymphocyte counts at diagnosis of opportunistic infection from 1990 to 1994 is shown. (Adapted from reference .) MAC, complex; CMV ret, CMV retinitis; Histo, Histoplasmosis; Toxo, toxoplasmosis; Crypt, cryptococcosis; Cocci, coccidiomycosis; Cand Esoph, Candida esophagitis; Cryptospor, cryptosporidiosis; dTB, disseminated tuberculosis; HSV, Herpes simplex virus; Strep Pneumo, PTB, pulmonary tuberculosis; Cervical CH, cervical carcinoma.

Citation: Masur H. 2000. Human Immunodeficiency Virus-Related Opportunistic Infections in the Era of Highly Active Antiretroviral Therapy, p 165-186. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 4. ASM Press, Washington, DC. doi: 10.1128/9781555816971.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2.
Figure 2.

Incidence of HIV-related opportunistic infections in CDC Adult Spectrum of Disease study. Adapted from reference 18 and reprinted from the ( ) with pennission. pt-yrs, patient-years.

Citation: Masur H. 2000. Human Immunodeficiency Virus-Related Opportunistic Infections in the Era of Highly Active Antiretroviral Therapy, p 165-186. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 4. ASM Press, Washington, DC. doi: 10.1128/9781555816971.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3.
Figure 3.

Percentage of persons with CD4 + T-lymphocyte counts <500 cells/l who had antiretroviral therapy (ART) prescribed, by year (Adult/Adolescent Spectrum of HIV Disease project, 1992 to 1997). Adapted from reference .

Citation: Masur H. 2000. Human Immunodeficiency Virus-Related Opportunistic Infections in the Era of Highly Active Antiretroviral Therapy, p 165-186. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 4. ASM Press, Washington, DC. doi: 10.1128/9781555816971.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 4.
Figure 4.

Percentage of persons with CD4 T-Lymphocyte counts of <2001/l who had prophylaxis for pneumonia prescribed, by year (Adult/ Adolescent Spectrum of HIV Disease project, 1992 to 1997). Adapted from reference . TMP-SMX, trimethoprim-sulfamethoxazole.

Citation: Masur H. 2000. Human Immunodeficiency Virus-Related Opportunistic Infections in the Era of Highly Active Antiretroviral Therapy, p 165-186. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 4. ASM Press, Washington, DC. doi: 10.1128/9781555816971.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 5.
Figure 5.

Percentage of persons with CD4 T.lymphocyte counts of <50 cells/l. d who had prophylaxis for complex prescribed, by year (Adult/ Adolescent Spectrum of HIV Disease project, 1992 to 1997). Adapted from reference .

Citation: Masur H. 2000. Human Immunodeficiency Virus-Related Opportunistic Infections in the Era of Highly Active Antiretroviral Therapy, p 165-186. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 4. ASM Press, Washington, DC. doi: 10.1128/9781555816971.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555816971.chap12
1. Baldanti, F.,, M. R. Underwood,, S. C. Stanat,, K. K. Biron,, S. Chou,, A. Sarasini,, E. Silini,, G. Gema. 1996. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, whole mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70:13901395.
2.Centers for Disease Control. 1981. Pneumocystis pneumonia-Los Angeles. Morb. Mortal. Wkly. Rep. 30:250252.
3.Centers for Disease Control. 1989. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. Morb. Mortal. Wkly. Rep. 38S:19.
3.a. Centers for Disease Control. 1991. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 40(RR-13).
3.b. Centers for Disease Control and Prevention. 1996. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 45(RR-15).
3.c. Centers for Disease Control and Prevention. 1999. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 48(RR-4).
4.Centers for Disease Control and Prevention. 1999. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). Morb. Mortal. Wkly. Rep. 48(RR-10):166.
5.Centers for Disease Control andPrevention. 1999. HIV/AIDS Surveillance Rep. 11(1):143
6. Chien, J. W.,, and J. L. Johnson. 1998. Paradoxical reactions to HIV and pulmonary TB. Chest 114:933936.
7. Chou, S.,, S. Guentzel,, K. R. Michels,, R. C. Miner,, and W. L. Drew. 1995. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J. Infect. Dis. 172:239242.
8.Department of Health and Human Services and Henry J. Kaiser Foundation. 1998. Guidelines for the use of antiretroviral agents in the HIV-infected adults and adolescents. Ann. Intern. Med. 128:1079100. (Updated: http://www.hivatis.org.)
9. Diaz-Guerra, T. M.,, J. V. Martinez-Suarez,, F. Laguna,, E. Valencia,, and J. L. Rodriguez-Tudela. 1998. Change in fluconazole susceptibility patterns and genetic relationship among oral Candida albicans isolates. AIDS 12:16011610.
10. Edwards, J. E.Jr., , G. P. Bodey,, R. A. Bowden,, T. Buchner,, B. E. de Pauw,, S. G. Finer,, M. A. Ghannoum,, M. Glauser,, R. Herbrecht,, C. A. Kauffman,, S. Kohno,, P. Martino,, F. Meunier,, T. Mon,, M. A. Pfaller,, J. H. Rex,, T. R. Rogers,, R. H. Rubin,, J. Solomkin,, C. Viscoli,, T. J. Walsh,, and M. White. 1997. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidial Infections. Clin. Infect. Dis. 25:4359.
11. Farizo, K. M.,, J. W. Buehler,, M. E. Chamberland,, B. M. Whyte,, E. S. Froelicher,, S. G. Hopkins,, C. M. Reed,, E. D. Mokotoff,, D. L. Cohn,, and S. Troxler. 1992. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 267:17981805.
12. Furrer, H.,, M. Egger,, M. Opravil,, E. Bernasconi,, B. Hirschel,, M. Battegay,, A. Telenti,, P. L. Vernazza,, M. Rickenbach,, M. Flepp,, and R. Malinverni. 1999. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HlV-I-infected adults treated with combination antiretroviral therapy. N. Engl. J. Med. 340:13011306.
13. Gottlieb, M. S.,, R. Schroff,, H. M. Schanker,, J. D. Weisman,, P. T. Fan,, R. A. Wolf,, and A. Saxon. 1981. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 305:14251431.
14. Gruilich, A. E. 1999. AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy. J. Acquired Immune Defic. Syndr. 21(Suppl):S2730.
15. Hardy, W. D.,, J. Feinberg,, D. M. Finkelstein,, M. E. Power,, W. He,, C. Kaczka,, P. T. Frame,, M. Holmes,, H. Waskin,, and R. J. Fass. 1992. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials group 021. N. Engl. J. Med. 327:18421848.
16. Heifets, L.,, P. Lindholm-Levy,, J. Libonati et al. 1993. Radiometric broth macrodilution method for determination of minimal inhibitory concentrations (MIC) with Mycobacterium avium complex isolates: proposed guidelines. National Jewish Center for Immunology and Respiratory Medicine, Denver, Col.
17. Helweg-Larsen, J.,, T. L. Benfield,, J. Eugen-Olsen,, J. D. Lundgren,, and B. Lundgren. 1999. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AlDS-associated P. carinii pneumonia. Lancet 354:13471351.
18. Jones, J. L.,, D. L. Hanson,, M. S. Dworkin, et al. 1999. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. Morb. Mortal. Wkly. Rep. 48(SS-2):122.
19. Kaplan, J.,, and H. Masur. 1999. Does Pneumocystis carinil prophylaxis still need to be life-long? N. Engl. J. Med. 340:13561358.
20. Karavellas, M. P.,, D. J. Plummer,, J. C. Macdonald,, F. J. Torriani,, C. L. Shufelt,, S. P. Azen,, and W. R. Freeman. 1999. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J. Infect. Dis. 179:697700.
21. Kazanjian, P.,, A. B. Locke,, P. A. Hossler,, B. R. Lane,, M. S. Bartlett,, J. W. Smith,, M. Cannon,, and S. R. Meshnick. 1998. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS 12:873878.
22. Kirk, O.,, J. D. Lnndgren,, C. Pedersen,, H. Nielsen,, and J. Gerstoft 1999. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS 13:16471651.
22.a. Kovacs, J. A.,, and H. Masur. 2000. Prevention of HIV-related opportunistic infections. N. Engl. J. Med. 342:14161429.
23. Ma, L.,, L. Borio,, H. Masur,, and J. A. Kovacs. 1999. Pneumocystis carinii dihydopteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J. Infect. Dis. 180:19691978.
24. Macdonald, C. J.,, F. J. Torriani,, L. S. Morse,, M. P. Karavellas,, J. B. Reed,, and W. R. Freeman. 1998. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J. Infect. Dis. 177:11821187.
25. Masur, H.,, M. A. Michelis,, J. B. Greene,, I. Onorato,, R. A. Stouwe,, R. S. Holzman,, G. Wormser,, L. Brettman,, M. Lange,, H. W. Murray,, and S. Cunningham.Rundles. 1981. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N. Engl. J. Med. 305:14311438.
26. McKenzie, R.,, W. D. Travis,, S. Dolan,, S. Pittaluga,, I. M. Feuerstein,, J. Shelhamer,, R. Yarchoan,, and H. Masur. 1991. The causes of death in patients with human immunodeficiency virus infection- A clinical and pathological study with emphasis on the role on pulmonary diseases. Medicine 70:326343.
26.a. McNaghten, A. D.,, D. L. Hanson,, J. L. Jones,, M. S. Dworkin,, J. W. Ward, and the Adultl Adolescent Spectrum of Disease Group. 1999. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. AIDS 13:16871695.
27. Miller, v.,, A. Mocron,, P. Reiss,, C. Katlama,, A. I. Papadopoulos,, T. Katzenstein,, J. van Lunzen,, F. Antunes,, A. N. Phillips,, and J. D. Lundgren. 1999. Relations among CD4 lymphocyte court nadir, antiretroviral therapy. and HIV-l disease progression: results from the EuroSIDA study. Ann. Intern. Med. 130:570577.
28. Moore, R. D.,, and R. E. Chaisson. 1996. Natural history of opportunistic diseases in an HIV-infected urban clinical cohort. Ann. Intern. Med. 124:633642.
29. Narita, M.,, D. Ashkin,, E. S. Hollender,, and A. E. Pitchenik. 1998. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am. J. Respir. Crit. Care Med. 158:157161.
30. Nielsen, H.,, B. Kvinesdal,, T. L. Benfield,, J. D. Lundgren,, and H. B. Konradsen. 1999. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-l infection. Scan. J. Infect. Dis. 30:597601.
31. Palella, F. J., Jr, K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853860.
32. Pierce, M.,, S. Crampton,, D. Henry,, L. Heifets,, A. LaMarca,, M. Montecalvo,, G. P. Wormser,, H. Jablonowski,, J. Jemsek,, M. Cynamon,, B. G. Yangco,, G. Notario,, and J. C. Craft 1996. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N. Engl. J. Med. 335:384391.
33. Powderly, W. G.,, K. H. Mayer,, and J. R. Perfect. 1999. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res. Hum. Retrovir. 15:14051412.
34. Race, E. M.,, J. Adelson-Mitty,, G. R. Kriegel,, T. F. Barlam,, K. A. Reimann,, N. L. Letvin,, and A. J. Japour. 1998. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced mV-l disease. Lancet 351:252255.
35. Revankar, S. G.,, O. P. Dib,, W. R. Kirkpatrick,, R. K. McAtee,, A. W. Fothergill,, M. G. Rinaldi,, S. W. Redding,, and T. F. Patterson. 1998. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 26:960963.
36. Rex, J. H.,, M. A. Pfaller,, J. N. Galgiani,, M. S. Bartlett,, A. Espinel.lngrotT, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin. Infect. Dis. 24:235247.
37. Schneider, M. M.,, J. C. Borleffs,, R. P. Stolk,, C. A. Jaspers,, and A. I. Hoepelman. 1999. Discontinuation of Pneumocystis carinii pneumonia prophylaxis in HIV-l infected patients treated with highly active antiretroviral therapy. Lancet 353:201203.
38. Siegal, F. P.,, C. Lopez,, G. S. Hammer,, A. E. Brown,, S. J. Kornfeld,, J. Gold,, J. Hassett,, S. Z. Hirschman,, C. Cunningham-Rundles,, and B. R. Adelsberg. 1981. Severe acquired immunodeficiency in male homosexuals manifested by chronic perianal ulcerative herpes simplex lesions. N. Engl. J. Med. 305:14391444.
39. Tatarowicz, W. A.,, N. S. Lurain,, and K. D. Thompson. 1992. A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J. Infect. Dis. 166:904907.
40. Thral, C.,, J. Romeu,, G. Sirera,, D. Andreu,, M. Conejero,, S. Ruiz,, A. Jou,, A. Bonjoch,, L. Ruiz,, A. Arno,, and B. Clotet. 1998. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J. Infect. Dis. 177:10801083.
41. van der Giessen, J. W.,, A. Eger,, J. Haagsma,, and B. A. van der Zeijst. 1993. Rapid detection and identification of Mycobacterium avium by amplification of 16s rRNA sequences. J. Clin. Microbiol. 31:25092512.
42. Vrabec, T. R.,, V. F. Baldassano,, and S. M. Whitcup. 1998. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology 105:12591264.
43. Weverling, G. J.,, A. Mocroft,, B. Ledergerber,, O. Kirk,, J. Gonzales-Lahoz,, A. d' Arminio Monforte,, R. Proenca,, A. N. Phillips,, J. D. Lundgren,, and P. Reiss. 1999. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in mV-l infection. Lancet 353:12931298.
44. Whitcup, S. M.,, E. Fortin,, A. S. Lindblad,, P. Griffiths,, J. A. Metcalf,, M. R. Robinson,, J. Manischewitz,, B. Baird,, C. Perry,, I. M. Kidd,, T. Vrabec,, R. T. Davey, Jr.,, J. Falloon,, R. E. Walker,, J. A. Kovacs,, H. C. Lane,, R. B. Nussenblatt,, J. Smith,, H. Masur,, and M. A. Polis. 1999. Discontinuation of specific anti-cytomegalovirus therapy in persons with HIV infection and cytomegalovirus retinitis on HAART. JAMA 282:16331637.
45. Yangco, B. G.,, J. C. Von Bargen,, A. C. Moorman,, and S. D. Holmberg. 2000. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. Ann. Intern. Med. 132:201205.

Tables

Generic image for table
Table 1.

Prophylaxis to prevent the first episode of opportunistic disease in adults and adolescents infected with HIV

Citation: Masur H. 2000. Human Immunodeficiency Virus-Related Opportunistic Infections in the Era of Highly Active Antiretroviral Therapy, p 165-186. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 4. ASM Press, Washington, DC. doi: 10.1128/9781555816971.ch12

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error